Another combination therapy with dapagliflozin and saxagliptin ameliorated diabetic cardiomyopathy and diabetic nephropathy in mice by inhibiting proinflammatory cytokines and NLRP3/ASC inflammasome production [15, 64]. Here, NLRP3 is linked to diabetic cardiomyopathy.